ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 512,84
0,32%
DAX
18 772,85
0,50%
Brent Oil
82,585
0,00%
Bitcoin
61 296,89
0,82%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Lipocine Inc (LPCN)

  7. Lipocine Inc (LPCN) Actualités

LPCN

Lipocine (LPCN)

Lipocine Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:LPCN
DateHeureSourceTitreSymboleSociété
09/05/202414h00PR Newswire (US)Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024NASDAQ:LPCNLipocine Inc
09/05/202412h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPCNLipocine Inc
09/05/202412h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
08/05/202414h00PR Newswire (US)Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024NASDAQ:LPCNLipocine Inc
01/05/202414h00PR Newswire (US)Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154NASDAQ:LPCNLipocine Inc
11/04/202413h00PR Newswire (US)Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityNASDAQ:LPCNLipocine Inc
28/03/202413h00PR Newswire (US)Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisNASDAQ:LPCNLipocine Inc
25/03/202413h00PR Newswire (US)Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
07/03/202414h00PR Newswire (US)Lipocine Announces Financial Results for the Full Year Ended December 31, 2023NASDAQ:LPCNLipocine Inc
07/03/202412h07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LPCNLipocine Inc
06/03/202414h00PR Newswire (US)Lipocine to Present at 36th Annual Roth ConferenceNASDAQ:LPCNLipocine Inc
06/02/202414h00PR Newswire (US)Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
02/02/202414h00PR Newswire (US)Lipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsNASDAQ:LPCNLipocine Inc
18/01/202414h00PR Newswire (US)Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and CanadaNASDAQ:LPCNLipocine Inc
19/12/202314h00PR Newswire (US)Lipocine to Present at Biotech Showcase 2024NASDAQ:LPCNLipocine Inc
22/11/202322h15Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LPCNLipocine Inc
13/11/202320h45PR Newswire (US)Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023NASDAQ:LPCNLipocine Inc
08/11/202314h00PR Newswire (US)Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023NASDAQ:LPCNLipocine Inc
01/11/202313h00PR Newswire (US)Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023NASDAQ:LPCNLipocine Inc
26/10/202314h00PR Newswire (US)Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum DepressionNASDAQ:LPCNLipocine Inc
24/10/202301h00PR Newswire (US)Lipocine to Present at the H.C. Wainwright Annual NASH Investor ConferenceNASDAQ:LPCNLipocine Inc
19/09/202322h05PR Newswire (US)Lipocine to Present at the Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:LPCNLipocine Inc
10/08/202314h00PR Newswire (US)Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023NASDAQ:LPCNLipocine Inc
27/07/202312h30PR Newswire (US)LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with CirrhosisNASDAQ:LPCNLipocine Inc
26/06/202315h21Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LPCNLipocine Inc
14/06/202314h00PR Newswire (US)Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual ConferenceNASDAQ:LPCNLipocine Inc
07/06/202314h00PR Newswire (US)Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023NASDAQ:LPCNLipocine Inc
25/05/202321h11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LPCNLipocine Inc
16/05/202313h00PR Newswire (US)Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of DepressionNASDAQ:LPCNLipocine Inc
11/05/202312h00PR Newswire (US)Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023NASDAQ:LPCNLipocine Inc
 Showing the most relevant articles for your search:NASDAQ:LPCN

Dernières Valeurs Consultées

NASDAQ
AAPL
Apple
COIN
BTCUSD
Bitcoin
NYSE
KO
Coca Cola
NASDAQ
AMZN
Amazon.com
EU
BEL20
Bel 20
EU
SGO
Cie de SaintGobain
NASDAQ
NVDA
NVIDIA
COIN
ETHUSD
Ethereum
EU
AI
Air Liquide
EU
HO
Thales
SPI
SP500
S&P 500
EU
MC
Lvmh Moet Hennessy Louis...
EU
ORA
Orange
NYSE
NKE
Nike
EU
ML
Michelin
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés